{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:37:07Z","timestamp":1762101427214},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,5,11]],"date-time":"2013-05-11T00:00:00Z","timestamp":1368230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s10384-013-0245-9","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T00:29:50Z","timestamp":1368145790000},"page":"365-371","source":"Crossref","is-referenced-by-count":20,"title":["Treatment results at 1\u00a0year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity"],"prefix":"10.1007","volume":"57","author":[{"given":"Ryusaburo","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuko","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Akaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,11]]},"reference":[{"key":"245_CR1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"245_CR2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"245_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bjo.2009.159160","volume":"94","author":"P Mitchell","year":"2010","unstructured":"Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Pr\u00fcnte C, Schmidt-Erfurth U, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94:2\u201313.","journal-title":"Br J Ophthalmol"},{"key":"245_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199001010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1\u20138.","journal-title":"Retina."},{"key":"245_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bjo.86.3.321","volume":"86","author":"H Terasaki","year":"2002","unstructured":"Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol. 2002;86:321\u20137.","journal-title":"Br J Ophthalmol"},{"key":"245_CR6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bjo.2003.032466","volume":"88","author":"M Matsuoka","year":"2004","unstructured":"Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004;88:809\u201315.","journal-title":"Br J Ophthalmol"},{"key":"245_CR7","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1167\/iovs.08-2134","volume":"49","author":"H Nakashizuka","year":"2008","unstructured":"Nakashizuka H, Mitsumata M, Okisaka S, Shimada H, Kawamura A, Mori R, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:4729\u201337.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"245_CR8","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of subRPE lesions photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453\u201364.","journal-title":"Retina."},{"key":"245_CR9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/112067210801800427","volume":"18","author":"J Reche-Frutos","year":"2008","unstructured":"Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J, Leila M, Garcia-Sanchez J. Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol. 2008;18:645\u20138.","journal-title":"Eur J Ophthalmol"},{"issue":"674\u201382","key":"245_CR10","first-page":"e1","volume":"150","author":"T Hikichi","year":"2010","unstructured":"Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3\u00a0months. Am J Ophthalmol. 2010;150(674\u201382):e1.","journal-title":"Am J Ophthalmol"},{"key":"245_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjo.2008.150029","volume":"94","author":"GT Kokame","year":"2010","unstructured":"Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol. 2010;94:297\u2013301.","journal-title":"Br J Ophthalmol"},{"key":"245_CR12","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/IAE.0b013e318236e503","volume":"32","author":"M Saito","year":"2012","unstructured":"Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina. 2012;32:1250\u20139.","journal-title":"Retina."},{"key":"245_CR13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajo.2011.12.019","volume":"154","author":"T Hikichi","year":"2012","unstructured":"Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol. 2012;154:117\u201324.","journal-title":"Am J Ophthalmol"},{"issue":"585","key":"245_CR14","first-page":"e6","volume":"115","author":"Y Tano","year":"2008","unstructured":"Tano Y. Ophthalmic PDT Study Group. Guidelines for PDT in Japan. Ophthalmology. 2008;115(585):e6.","journal-title":"Ophthalmology."},{"key":"245_CR15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00006982-200210000-00001","volume":"22","author":"RF Spaide","year":"2002","unstructured":"Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina. 2002;22:529\u201335.","journal-title":"Retina."},{"key":"245_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/0301-4738.16172","volume":"53","author":"N Hussain","year":"2005","unstructured":"Hussain N, Hussain A, Natarajan S. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Indian J Ophthalmol. 2005;53:101\u20134.","journal-title":"Indian J Ophthalmol"},{"key":"245_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000076844","volume":"218","author":"SC Lee","year":"2004","unstructured":"Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica. 2004;218:193\u2013201.","journal-title":"Ophthalmologica."},{"key":"245_CR18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","volume":"111","author":"WM Chan","year":"2004","unstructured":"Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576\u201384.","journal-title":"Ophthalmology"},{"key":"245_CR19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00417-005-1139-4","volume":"243","author":"RM Silva","year":"2005","unstructured":"Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2005;243:973\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"245_CR20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/112067210601600506","volume":"16","author":"M Mauget-Fa\u00ffsse","year":"2006","unstructured":"Mauget-Fa\u00ffsse M, Quaranta-El Maftouhi M, De La Marni\u00e8rre E, Leys A. Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy. Eur J Ophthalmol. 2006;16:695\u2013704.","journal-title":"Eur J Ophthalmol"},{"key":"245_CR21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2007.02.031","volume":"115","author":"F Gomi","year":"2008","unstructured":"Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141\u20136.","journal-title":"Ophthalmology"},{"key":"245_CR22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10384-007-0452-3","volume":"51","author":"E Akaza","year":"2007","unstructured":"Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2007;51:270\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"245_CR23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ajo.2009.09.020","volume":"149","author":"A Yamashita","year":"2010","unstructured":"Yamashita A, Shiraga F, Shiragami C, Ono A, Tenkumo K. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:465\u201371.","journal-title":"Am J Ophthalmol"},{"key":"245_CR24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","volume":"133","author":"M Uyama","year":"2002","unstructured":"Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639\u201348.","journal-title":"Am J Ophthalmol"},{"key":"245_CR25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/08820530701421635","volume":"22","author":"M Ghajarnia","year":"2007","unstructured":"Ghajarnia M, Kurup S, Eller A. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy. Semin Ophthalmol. 2007;22:127\u201331.","journal-title":"Semin Ophthalmol."},{"key":"245_CR26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","volume":"92","author":"F Gomi","year":"2008","unstructured":"Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:70\u20133.","journal-title":"Br J Ophthalmol"},{"key":"245_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000175312","volume":"223","author":"JH Song","year":"2009","unstructured":"Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW. Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica. 2009;223:85\u201392.","journal-title":"Ophthalmologica."},{"key":"245_CR28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ajo.2009.12.038","volume":"149","author":"T Sato","year":"2010","unstructured":"Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:947\u201354.","journal-title":"Am J Ophthalmol"},{"key":"245_CR29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10384-010-0813-1","volume":"54","author":"A Tsujikawa","year":"2010","unstructured":"Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2010;54:310\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"245_CR30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/IAE.0b013e31816577cb","volume":"28","author":"E Akaza","year":"2008","unstructured":"Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina. 2008;28:717\u201322.","journal-title":"Retina."},{"key":"245_CR31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00417-007-0582-9","volume":"245","author":"K Sayanagi","year":"2007","unstructured":"Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y. Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2007;245:1569\u201371.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"245_CR32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10384-010-0886-x","volume":"55","author":"E Akaza","year":"2011","unstructured":"Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:39\u201344.","journal-title":"Jpn J Ophthalmol."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-013-0245-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-013-0245-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-013-0245-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T12:40:26Z","timestamp":1563021626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-013-0245-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1007\/s10384-013-0245-9","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,11]]}}}